Navigation Links
Researchers pinpoint genetic pathways involved in breast cancer
Date:3/3/2011

EAST LANSING, Mich. Using recent advances in genomics, researchers have uncovered a genetic pathway that affects the development of breast cancer, work that could help predict which patients are at risk of relapse for the disease.

By studying which genes are expressed or "turned on" in breast cancer, research led by Michigan State University's Eran Andrechek uncovered a role for several members of the E2F family of genes, which control cell division and growth.

Specifically, Andrechek's team found the activation of the specific gene E2F2 was associated with a higher probability of breast cancer relapse in humans. The research team, using rodent models, also found that removing the E2F2 gene significantly decreased the likelihood of a tumor.

The findings, to be published in the journal Cancer Research, are available online now.

"Genomic signatures how genes interact and via what pathways are a rapidly growing and a powerful method to analyze specific genes in the development, recurrence and spread of breast cancer," said Andrechek, an assistant professor in the MSU Department of Physiology and lead author of the paper.

After identifying which genes are being activated, physicians can tailor treatments for breast cancer and other diseases to individuals with certain genetic makeups. For example, breast cancer patients with over-expression of a gene called HER2 are currently treated with the antibody Herceptin, which specifically targets the cells over-expressing HER2.

"With personalized medicine, we can use predictions of how genes will interact, and based on that we can make better use of existing treatments that will have more of an impact," Andrechek said.

As part of the research, Andrechek and his team focused on tumors initiated by Myc, a gene that is amplified in 15 percent of all human breast cancer cases. The team then analyzed the tumors to test which pathways were critical to tumor growth, first in computer models and then in rodent models.

In addition to the discovery of E2F2's role in tumor incidence and relapse, the research also revealed the gene was critical for the development of a type of basal tumor. These tumors are similar to the so-called "triple negative tumors" in human breast cancer that are more prevalent among blacks and are much more difficult to treat.

The article can be viewed online at http://cancerres.aacrjournals.org/content/early/2011/01/18/0008-5472.CAN-10-2386.abstract. Other contributing authors included Kenichiro Fujiwara, Inez Yuwanita, and Daniel Hollern.

An extension of Andrechek's work has recently been funded by the Elsa U. Pardee Foundation a Michigan organization that has given more than $113 million in grants for cancer research to explore therapy options based on genomic profiles.

"We want to examine how we can design therapies for specific tumor types by combining genomics and current medicines," he said. "We feel this holds great promise for personalized cancer therapy."


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Related medicine news :

1. Penn researchers find new role for cancer protein p53
2. UCSF researchers uncover hormone pathway to fatty liver disease
3. Researchers pinpoint patients who receive greatest benefit from heart failure treatment
4. IDIBELL researchers discover a substance against the dark genome of cancer
5. Wayne State University researchers publish results settling multiple sclerosis debate
6. E-health must be a priority, researchers say
7. Mayo Clinic researchers confirm value of therapeutic hypothermia after cardiac arrest
8. Mayo researchers, Rochester educators, students to present at science conference
9. Researchers work at the frontiers of islet cell transplantation
10. Brain Appears to Be a Task Machine, Researchers Say
11. Researchers develop outline that may help weigh benefits of new imaging technologies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers pinpoint genetic pathways involved in breast cancer
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: